Endocrine Pharmacology: Oral Contraceptives and Emergency Contraception

1 Introduction/Overview

Clinical Relevance and Importance

Hormonal contraceptives remain among the most widely used therapeutic agents for reproductive health worldwide. Oral contraceptive pills (OCPs) and emergency contraceptive (EC) formulations provide effective methods for preventing unintended pregnancy, managing menstrual disorders, and addressing specific gynecologic conditions. The prevalence of OCP use, estimated to exceed 30% of reproductive-age women in many high-income countries, underscores the necessity for a comprehensive understanding of their pharmacologic profiles among clinicians and pharmacists. Emergency contraception, which offers a post‑coital option for preventing pregnancy, has evolved from the Yuzpe regimen to levonorgestrel and ulipristal acetate, expanding therapeutic choices and influencing public health strategies.

Learning Objectives

• Describe the chemical and pharmacologic classification of oral contraceptives and emergency contraceptive agents.
• Explain the mechanisms of action, including endocrine and reproductive tract effects, for both combined and progestin‑only oral contraceptives, as well as for levonorgestrel, ulipristal acetate, and copper intrauterine devices.
• Summarize the key pharmacokinetic parameters that influence dosing schedules and therapeutic outcomes.
• Identify common adverse effects, serious complications, and black‑box warnings associated with these agents.
• Recognize major drug interactions, contraindications, and special considerations for distinct patient populations.

2 Classification

Drug Classes and Categories

Oral contraceptives are grouped into two principal categories:

1. Combined estrogen‑progestin (C‑EP) oral contraceptives – typically contain ethinyl estradiol (EE) plus a progestin such as levonorgestrel, drospirenone, or desogestrel.
2. Progestin‑only oral contraceptives (POPs) – include micronized progesterone, norethindrone, and newer progestins such as dienogest and nomegestrol acetate.

Emergency contraception is classified into pharmacologic and device‑based options:

• Levonorgestrel (LNG) tablets – single‑dose or dual‑dose regimens.
• Ulipristal acetate (UPA) – selective progesterone receptor modulator administered as a single 30‑mg dose.
• High‑dose estrogen‑progestin (Yuzpe regimen) – combination of EE and levonorgestrel in multiple doses.
• Copper intrauterine device (Cu‑IUD) – non‑hormonal device providing immediate and long‑term EC.

Chemical Classification

Estrogens in C‑EP formulations are predominantly synthetic analogues of estradiol, with ethinyl estradiol representing the most widely used derivative. Progestins are structurally diverse; early generation compounds (e.g., norethindrone) share a 19‑norprogesterone backbone, whereas newer agents (e.g., drospirenone) possess a spirolactone structure conferring antimineralocorticoid activity. Progestin‑only agents include both synthetic progestins and micronized natural progesterone, the latter differing in bioavailability and metabolic pathways. Ulipristal acetate is a selective progesterone receptor modulator featuring a 17‑hydroxyprogestin core with a unique side chain that confers partial agonist/antagonist activity. The copper IUD’s mechanism relies on the release of Cu²⁺ ions, generating an inflammatory milieu detrimental to sperm viability.

3 Mechanism of Action

Pharmacodynamics of Combined Estrogen‑Progestin Oral Contraceptives

Estrogen and progestin components exert negative feedback on the hypothalamic‑pituitary‑gonadal axis. Estrogen suppresses gonadotropin‑releasing hormone (GnRH) pulse frequency, while progestin further dampens luteinizing hormone (LH) surges. The combined effect reduces follicular recruitment and arrests ovulation during the follicular phase. Progestin also induces thickening of cervical mucus, limiting sperm penetration, and alters the endometrial lining, rendering implantation less favorable.

Pharmacodynamics of Progestin‑Only Oral Contraceptives

POPs primarily function by thickening cervical mucus and modulating endometrial receptivity. Ovulation may still occur, particularly in low‑dose regimens, but the altered cervical environment and endometrial changes decrease the likelihood of fertilization and implantation.

Emergency Contraception – Levonorgestrel

Levonorgestrel, a potent progestin, primarily delays or inhibits ovulation when administered within 24–72 hours post‑coitus. It binds progesterone receptors on granulosa and theca cells, suppressing LH surges and preventing the maturation of the dominant follicle. Additional effects include alteration of the fallopian tube environment, reducing sperm capacitation and ovum fertilization. In some instances, levonorgestrel may impair implantation, though evidence remains limited.

Emergency Contraception – Ulipristal Acetate

Ulipristal acetate exerts selective progesterone receptor modulation. By antagonizing the progesterone receptor, it inhibits the LH surge and prevents the final maturation of the follicle. Its efficacy is maintained up to 120 hours post‑coitus, offering an extended therapeutic window compared to levonorgestrel. Ulipristal also induces changes in the uterine epithelium, reducing invasiveness of the embryo.

Emergency Contraception – Copper IUD

Insertion of the copper IUD within five days of unprotected intercourse creates a pro‑inflammatory environment characterized by elevated prostaglandin and cytokine levels. Copper ions exert direct cytotoxicity on sperm, impair motility and viability, and induce oxidative stress. The device’s presence also alters endometrial receptivity, preventing implantation. The copper IUD remains effective for up to five years as a reversible contraceptive.

Receptor Interactions and Molecular Signaling

Both estrogen and progestin components act on nuclear receptors (ERα, ERβ, PR) to modulate gene transcription. Estrogen receptors influence cyclin‑dependent kinase inhibitors, thereby halting follicular growth. Progestins inhibit cAMP production in granulosa cells, suppressing luteinizing hormone‑stimulated steroidogenesis. Ulipristal’s partial agonist/antagonist profile yields selective modulation of PR‑mediated transcriptional activity, with downstream effects on the hypothalamic‑pituitary axis. The copper IUD’s mechanism is mediated through non‑receptor pathways, primarily via ionic and inflammatory mediators.

4 Pharmacokinetics

Absorption

Oral contraceptives achieve high bioavailability (>90%) following ingestion. Estrogen absorption is influenced by first‑pass hepatic metabolism, whereas progestin absorption is largely unaffected. Levonorgestrel exhibits rapid absorption with a median t_max of approximately 1–2 hours. Ulipristal acetate demonstrates a t_max of 1–2 hours and high oral bioavailability (~50–60%). Copper ions from the IUD are released locally within the uterus, with systemic absorption negligible.

Distribution

Estrogens bind extensively to sex hormone‑binding globulin (SHBG) and albumin; progestins exhibit variable protein binding (typically 30–80%). Levonorgestrel and ulipristal have moderate plasma protein binding, allowing for adequate tissue penetration. Distribution volumes for levonorgestrel approximate 70 L, reflecting extensive tissue uptake. Ulipristal’s volume of distribution is larger (~200 L), indicating broad tissue distribution.

Metabolism

Cytochrome P450 enzymes, predominantly CYP3A4, mediate hepatic metabolism. Estrogens undergo conjugation via glucuronidation and sulfation. Progestins, including levonorgestrel, are metabolized by CYP3A4 to active or inactive metabolites. Ulipristal acetate is extensively metabolized by CYP3A4 and CYP2C19, yielding metabolites with reduced activity. The copper IUD’s components are not systemically metabolized.

Excretion

Metabolites of estrogens and progestins are excreted primarily via the biliary route into feces, with a minor renal component. Levonorgestrel metabolites are eliminated through fecal excretion (≈85%) and urine (≈15%). Ulipristal’s metabolites follow a similar pattern, with fecal excretion predominating. Copper ions are sequestered locally; systemic excretion is negligible.

Half‑Life and Dosing Considerations

Estrogen half‑life (t_1/2) ranges from 4–6 hours, whereas progestin half‑lives are longer, approximately 24–30 hours for levonorgestrel. The elimination constant (k_el) can be calculated via C(t) = C₀ × e^-k_elt, with t_1/2 = 0.693 ÷ k_el. Levonorgestrel’s t_1/2 is roughly 24 hours, supporting once‑daily dosing for combined OCPs. Ulipristal acetate possesses a t_1/2 of ≈30 hours, enabling a single‑dose regimen for EC. For Cu‑IUDs, pharmacokinetic considerations are limited to local tissue exposure, with minimal systemic absorption.

5 Therapeutic Uses/Clinical Applications

Approved Indications

• Combined oral contraceptives: Primary prevention of pregnancy, regulation of menstrual cycles, reduction of dysmenorrhea, management of acne, and mitigation of endometrial hyperplasia.
• Progestin‑only oral contraceptives: Primary contraception for women with contraindications to estrogen, management of menorrhagia, and treatment of amenorrhea.
• Levonorgestrel EC: Post‑coital contraception within 72 hours of unprotected intercourse.
• Ulipristal acetate EC: Post‑coital contraception up to 120 hours after intercourse.
• Yuzpe regimen: Historically used EC within 72 hours, now largely supplanted by newer agents.
• Copper IUD: Immediate EC within five days and long‑term reversible contraception up to five years.

Off‑Label Uses

Combined oral contraceptives are occasionally employed for the treatment of polycystic ovary syndrome (PCOS) due to androgen suppression. Progestin‑only formulations are sometimes used in women with gallbladder disease or thromboembolic risk. Levonorgestrel has been utilized in luteal‑phase support protocols, though evidence is limited. Ulipristal is occasionally prescribed for endometriosis symptom control, given its modulatory effects on progesterone signaling. Copper IUDs are occasionally recommended for patients with unexplained infertility where a pro‑inflammatory milieu may enhance implantation rates, though this application remains experimental.

6 Adverse Effects

Common Side Effects

• Vaginal bleeding irregularities, breakthrough bleeding, or spotting.
• Headache, nausea, breast tenderness, and bloating.
• Weight changes, mood fluctuations, and acne exacerbation.
• For levonorgestrel EC – nausea, vomiting, abdominal pain, and fatigue.
• For ulipristal acetate – mild headache, nausea, and myalgia.
• For copper IUD – dysmenorrhea, increased menstrual flow, and cramping during insertion.

Serious or Rare Adverse Reactions

• Venous thromboembolism (VTE) and pulmonary embolism, particularly with combined OCPs in women >35 years or with smoking habits.
• Hepatic dysfunction, including cholestatic jaundice, hepatic adenoma, and rare liver failure.
• Allergic reactions to copper IUD, such as copper allergy or hypersensitivity.
• Drug‑induced liver injury following ulipristal acetate, albeit exceedingly uncommon.
• Ocular or neuro‑psychiatric complications reported in isolated cases, but causal relationships remain uncertain.

Black Box Warnings

Combined estrogen‑progestin oral contraceptives carry a black‑box warning for increased risk of thromboembolic events, cardiovascular disease, and breast cancer with prolonged use. Progestin‑only contraceptives lack a black‑box warning but still carry a relative risk for VTE in certain subgroups. Levonorgestrel and ulipristal acetate are not associated with black‑box warnings; however, clinicians are advised to exercise caution in women with pre‑existing thrombotic risk factors. Copper IUDs are not associated with black‑box warnings but carry a Category C label regarding pregnancy risk due to potential teratogenic effects if used during conception.

7 Drug Interactions

Major Drug‑Drug Interactions

• Cytochrome P450 inducers (e.g., rifampin, carbamazepine, phenobarbital, St. John’s wort) reduce plasma concentrations of estrogen and progestin, potentially compromising contraceptive efficacy. Levonorgestrel and ulipristal acetate are similarly affected, leading to increased risk of unintended pregnancy.
• Cytochrome P450 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir) may elevate estrogen and progestin levels, increasing the risk of thromboembolic events and hepatic toxicity.
• Anticonvulsants (e.g., phenytoin, valproate) can alter hormone metabolism, necessitating dose adjustments or alternative contraceptive strategies.
• HIV protease inhibitors (e.g., lopinavir, atazanavir) may both induce and inhibit CYP3A4, leading to unpredictable hormone levels.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) may reduce platelet aggregation, compounding the thrombotic risk of estrogen‑containing contraceptives.

Contraindications

• Pregnancy or suspected pregnancy.
• Active hepatic disease or cholestasis.
• History of thromboembolic disease or smoking in women >35 years.
• Severe uncontrolled hypertension.
• Known hypersensitivity to any component.
• Recent major surgery or trauma in women receiving levonorgestrel or ulipristal acetate as EC.
• Active breast cancer or estrogen‑sensitive malignancies.
• Untreated psychiatric conditions that may impair compliance with contraceptive use.

8 Special Considerations

Use in Pregnancy and Lactation

Oral contraceptives are contraindicated during pregnancy. Progestin‑only formulations may be considered for lactating women due to minimal estrogen transfer into breast milk; however, estrogen‑containing OCPs should be avoided to preserve milk supply. Levonorgestrel EC is contraindicated in pregnancy. Ulipristal acetate is contraindicated in pregnancy and should be used only when pregnancy is ruled out. Copper IUD placement during lactation is acceptable; local copper release does not affect lactation or infant safety.

Pediatric and Geriatric Considerations

Oral contraceptives are not indicated for pre‑pubertal patients. In adolescents, combined OCPs may aid in the management of acne and menorrhagia; however, counseling regarding potential thrombotic risk is essential. Elderly women (>65 years) should be evaluated for cardiovascular risk before initiating estrogen‑containing therapy. Progestin‑only options may be preferable in high‑risk populations. Levonorgestrel EC can be administered to adolescents, with counseling on contraception and sexual health. Ulipristal acetate is indicated for adolescents; however, data on long‑term safety are limited. Copper IUDs remain safe across age groups, though insertion may be more challenging in older women with uterine fibroids.

Renal and Hepatic Impairment

Estrogen and progestin metabolism is predominantly hepatic; therefore, hepatic impairment (Child‑Pugh B/C) may increase systemic exposure, necessitating dose reduction or alternative therapy. In patients with severe hepatic disease, estrogen‑containing OCPs may be contraindicated. Renal impairment has limited impact on drug clearance for oral contraceptives, but copper IUD placement may require caution in patients with severe renal failure due to altered copper handling. Ulipristal acetate’s pharmacokinetics are not significantly altered in mild to moderate renal impairment; however, dose adjustments in severe renal dysfunction are not well established.

9 Summary/Key Points

Bullet Point Summary

• Combined estrogen‑progestin oral contraceptives function primarily by inhibiting ovulation, thickening cervical mucus, and reducing endometrial receptivity.
• Progestin‑only oral contraceptives rely on cervical mucus alteration and endometrial changes; ovulation may still occur.
• Levonorgestrel EC inhibits ovulation within 72 hours; ulipristal acetate extends efficacy up to 120 hours via progesterone receptor modulation.
• Copper IUDs provide immediate EC and long‑term pregnancy prevention through local inflammatory mechanisms.
• Metabolism by CYP3A4 underlies significant drug interactions; inducers diminish efficacy, inhibitors increase adverse event risk.
• Black‑box warnings for combined OCPs emphasize thromboembolic risk; careful patient selection is essential.
• Special populations—pregnancy, lactation, pediatrics, geriatrics, renal/hepatic impairment—require tailored counseling and dosing strategies.

Clinical Pearls

• Rapid initiation of levonorgestrel EC within 24 hours maximizes efficacy; delayed administration still offers benefit but with reduced effectiveness.
• Ulipristal acetate remains the preferred EC option for women with CYP3A4 inducer exposure, as it retains efficacy despite enzyme induction.
• Copper IUD insertion within five days of unprotected intercourse offers equivalent efficacy to pharmacologic EC and provides ongoing contraception.
• Monitoring of liver function tests is advisable in long‑term combined OCP users, particularly those with pre‑existing hepatic conditions.
• Patients on antiepileptic drugs should be offered progestin‑only contraceptives to mitigate interaction‑mediated efficacy loss.

References

1. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
2. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
3. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
4. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
5. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
7. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
8. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.